Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
PMID: 20008905
2010
The Journal of antimicrobial chemotherapy
Abstract: Both PG and CG data suggest TAMs, not K65R selection, are the preferred resistance route, biased towards 215F selection.
Abstract: By PG at VF, 10/14 had selected for resistance mutations [2, K65R; 1, M184V; and 7, thymidine analogue mutations (TAMs) +/- M184V].
Abstract: For one subject who selected K65R at VF, both K65R-containing clones and TAM-containing clones (both T215A and T215F) were observed independently but not conjunctively in the same clone in a post-VF sample.
Abstract: No HIV clone contained both K65R and T215F/Y mutations, suggesting in vivo antagonism between the two mutations.
Result: A
N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
Introduction: Decreased susceptibility to tenofovir in vitro and in vivo is associated with the K65R mutation or the presence of three or more TAMs (e.g.
Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.
Abstract: BACKGROUND: We have shown that the K65R resistance mutation in HIV type-1 (HIV-1) reverse transcriptase (RT) is selected more rapidly in subtype C than subtype B HIV-1 in biochemical, cell culture and clinical studies.
Abstract: CONCLUSIONS: These results further establish a mechanistic basis for the exclusion of both K65R and TAMs on single templates as well as the preferential acquisition of K65R in subtype C viruses.
Abstract: Template-usage experiments demonstrated that subtype C nucleotide coding sequences caused RT to preferentially pause, leading to K65R acquisition.
Abstract: This new study now further establishes the basis for differential occurrence of both K65R and thymidine anal
Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.
PMID: 20124005
2010
Antimicrobial agents and chemotherapy
Abstract: A K65R mutation in HIV-1 reverse transcriptase can occur with the failure of tenofovir-, didanosine-, abacavir-, and, in some cases, stavudine-containing regimens and leads to reduced phenotypic susceptibility to these drugs and hypersusceptibility to zidovudine, but its clinical impact is poorly described.
Abstract: Given its tolerability, tenofovir may be the preferred agent over zidovudine even in the presence of the K65R mutation.
Abstract: In the presence of K65R, zidovudine and tenofovir are associated with similar reductions in HIV RNA levels.
Abstract: We identified isolates with the K65R mutation within the Stanford Resistance Database and a French cohort for which subsequent treatment and virological response data were available.
The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization.
PMID: 20164190
2010
The Journal of biological chemistry
Abstract: PMEO-DAPym-pp is incorporated more efficiently than (R)PMPA-pp by mutant K65R HIV-1 RT and is not as efficiently excised as (R)PMPA by HIV-1 RT containing thymidine analog mutations.
Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review.
PMID: 20185094
2010
The Lancet. Infectious diseases
Abstract: Thymidine-analogue mutations and the K65R mutation were less common.
Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.
PMID: 20334569
2010
AIDS research and human retroviruses
Abstract: Numerous crucial DRMs to NRTIs and NNRTIs could be recorded including TAMs of pathway 1 and K65R.
HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Abstract: The nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations found were as follows: 85% of the children had M184V/I, 23% had at least four thymidine analogue mutations, 12% had the Q151M complex, 5% had K65R, and 1% had the 69 insertion.
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
PMID: 20380480
2010
AIDS research and human retroviruses
Abstract: In the four FPV/r-treated VFs, baseline HIV TAMs combinations and/or PI mutations were detected in one by PG at VF (RT: L210W + T215C; PR: M46I + L76V) and three others by CA alone (RT: L210W + T215Y; RT: M41L; RT: K65R + K70R; PR: I47V); all four had study drug-associated mutations (CA detecting more HIV-1 resistance mut
Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals.
Abstract: BACKGROUND: Amdoxovir acts synergistically with zidovudine in vitro and the combination prevents or delays the selection of thymidine analogue and K65R mutations.
Intro
Introduction: As observed for the K65R variant, virus containing the L74V mutation remained sensitive to zidovudine.
Introduction: On the basis of the favourable mutational resistance mechanisms, counter-selection of K65R and TAMs, and synergistic antiviral activity, it is expected that coadministration of zidovudine with amdoxovir could delay the emergence of NRTI resistance and prolong treatment response.
Introduction: Previous reports suggest that the K65R mutation, which confers cross-resistance to DXG and amdoxovir, can revert zidovudine-resistant virus to zidovudine-sensitive virus.
HIV mutation literature information.
PMID: 
2010
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT